144 related articles for article (PubMed ID: 34075018)
1. The natural analgesic conolidine targets the newly identified opioid scavenger ACKR3/CXCR7.
Szpakowska M; Decker AM; Meyrath M; Palmer CB; Blough BE; Namjoshi OA; Chevigné A
Signal Transduct Target Ther; 2021 Jun; 6(1):209. PubMed ID: 34075018
[No Abstract] [Full Text] [Related]
2. The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides.
Meyrath M; Szpakowska M; Zeiner J; Massotte L; Merz MP; Benkel T; Simon K; Ohnmacht J; Turner JD; Krüger R; Seutin V; Ollert M; Kostenis E; Chevigné A
Nat Commun; 2020 Jun; 11(1):3033. PubMed ID: 32561830
[TBL] [Abstract][Full Text] [Related]
3. Discovery of conolidine derivative DS39201083 as a potent novel analgesic without mu opioid agonist activity.
Arita T; Asano M; Kubota K; Domon Y; Machinaga N; Shimada K
Bioorg Med Chem Lett; 2019 Aug; 29(15):1938-1942. PubMed ID: 31147104
[TBL] [Abstract][Full Text] [Related]
4. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa.
Takayama H
Chem Pharm Bull (Tokyo); 2004 Aug; 52(8):916-28. PubMed ID: 15304982
[TBL] [Abstract][Full Text] [Related]
5. Functions of the CXCL12 Receptor ACKR3/CXCR7-What Has Been Perceived and What Has Been Overlooked.
Koch C; Engele J
Mol Pharmacol; 2020 Nov; 98(5):577-585. PubMed ID: 32883765
[TBL] [Abstract][Full Text] [Related]
6. Feedback control of the CXCR7/CXCL11 chemokine axis by estrogen receptor α in ovarian cancer.
Benhadjeba S; Edjekouane L; Sauvé K; Carmona E; Tremblay A
Mol Oncol; 2018 Oct; 12(10):1689-1705. PubMed ID: 30051594
[TBL] [Abstract][Full Text] [Related]
7. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of conolidine, a potent non-opioid analgesic for tonic and persistent pain.
Tarselli MA; Raehal KM; Brasher AK; Streicher JM; Groer CE; Cameron MD; Bohn LM; Micalizio GC
Nat Chem; 2011 Jun; 3(6):449-53. PubMed ID: 21602859
[TBL] [Abstract][Full Text] [Related]
9. Allosteric peptide regulators of chemokine receptors CXCR4 and CXCR7.
Ehrlich A; Ray P; Luker KE; Lolis EJ; Luker GD
Biochem Pharmacol; 2013 Nov; 86(9):1263-71. PubMed ID: 23973527
[TBL] [Abstract][Full Text] [Related]
10. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
[TBL] [Abstract][Full Text] [Related]
11. Expression and function of the SDF-1 chemokine receptors CXCR4 and CXCR7 during mouse limb muscle development and regeneration.
Hunger C; Ödemis V; Engele J
Exp Cell Res; 2012 Oct; 318(17):2178-90. PubMed ID: 22766125
[TBL] [Abstract][Full Text] [Related]
12. Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists.
Szpakowska M; Meyrath M; Reynders N; Counson M; Hanson J; Steyaert J; Chevigné A
Biochem Pharmacol; 2018 Jul; 153():299-309. PubMed ID: 29530506
[TBL] [Abstract][Full Text] [Related]
13. A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models.
Salazar N; Carlson JC; Huang K; Zheng Y; Oderup C; Gross J; Jang AD; Burke TM; Lewén S; Scholz A; Huang S; Nease L; Kosek J; Mittelbronn M; Butcher EC; Tu H; Zabel BA
Mol Ther; 2018 May; 26(5):1354-1365. PubMed ID: 29606504
[TBL] [Abstract][Full Text] [Related]
14. Atypical chemokine receptor ACKR3/CXCR7 controls postnatal vasculogenesis and arterial specification by mesenchymal stem cells via Notch signaling.
Wei ST; Huang YC; Hsieh ML; Lin YJ; Shyu WC; Chen HC; Hsieh CH
Cell Death Dis; 2020 May; 11(5):307. PubMed ID: 32366833
[TBL] [Abstract][Full Text] [Related]
15. Human herpesvirus 8-encoded chemokine vCCL2/vMIP-II is an agonist of the atypical chemokine receptor ACKR3/CXCR7.
Szpakowska M; Dupuis N; Baragli A; Counson M; Hanson J; Piette J; Chevigné A
Biochem Pharmacol; 2016 Aug; 114():14-21. PubMed ID: 27238288
[TBL] [Abstract][Full Text] [Related]
16. The relevance of the chemokine receptor ACKR3/CXCR7 on CXCL12-mediated effects in cancers with a focus on virus-related cancers.
Freitas C; Desnoyer A; Meuris F; Bachelerie F; Balabanian K; Machelon V
Cytokine Growth Factor Rev; 2014 Jun; 25(3):307-16. PubMed ID: 24853339
[TBL] [Abstract][Full Text] [Related]
17. CXCR7 silencing inhibits the migration and invasion of human tumor endothelial cells derived from hepatocellular carcinoma by suppressing STAT3.
Wu Y; Tian L; Xu Y; Zhang M; Xiang S; Zhao J; Wang Z
Mol Med Rep; 2018 Aug; 18(2):1644-1650. PubMed ID: 29901083
[TBL] [Abstract][Full Text] [Related]
18. Atypical Chemokine Receptor 3 (ACKR3): A Comprehensive Overview of its Expression and Potential Roles in the Immune System.
Koenen J; Bachelerie F; Balabanian K; Schlecht-Louf G; Gallego C
Mol Pharmacol; 2019 Dec; 96(6):809-818. PubMed ID: 31040166
[TBL] [Abstract][Full Text] [Related]
19. Mutational Analysis of Atypical Chemokine Receptor 3 (ACKR3/CXCR7) Interaction with Its Chemokine Ligands CXCL11 and CXCL12.
Benredjem B; Girard M; Rhainds D; St-Onge G; Heveker N
J Biol Chem; 2017 Jan; 292(1):31-42. PubMed ID: 27875312
[TBL] [Abstract][Full Text] [Related]
20. CXCR7 expression correlates with tumor depth in cutaneous squamous cell carcinoma skin lesions and promotes tumor cell survival through ERK activation.
Hu SC; Yu HS; Yen FL; Chen GS; Lan CC
Exp Dermatol; 2014 Dec; 23(12):902-8. PubMed ID: 25256412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
